TipRanks
Advertisement
Advertisement

PCRX Stock Latest News

Pacira price target raised to $36.50 from $25 at RBC Capital
The FlyPacira price target raised to $36.50 from $25 at RBC Capital
14d ago
PCRX
VTRS
Pacira downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Pacira downgraded to Neutral from Buy at H.C. Wainwright
14d ago
PCRX
Pacira downgraded to Hold from Buy at Truist
PremiumThe Fly
Pacira downgraded to Hold from Buy at Truist
14d ago
PCRX
Why Is Pacira Pharmaceuticals Stock (PCRX) Up 44% Today?
PremiumMarket News
Why Is Pacira Pharmaceuticals Stock (PCRX) Up 44% Today?
14d ago
PCRX
VTRS
Pacira downgraded to Perform from Outperform at Oppenheimer
PremiumThe Fly
Pacira downgraded to Perform from Outperform at Oppenheimer
14d ago
PCRX
Pacira downgraded to Hold from Buy at Jefferies
PremiumThe FlyPacira downgraded to Hold from Buy at Jefferies
15d ago
PCRX
Pacira upgraded to Neutral from Underweight at JPMorgan
Premium
The Fly
Pacira upgraded to Neutral from Underweight at JPMorgan
15d ago
PCRX
VTRS
Pacira downgraded to Hold from Buy at Needham
Premium
The Fly
Pacira downgraded to Hold from Buy at Needham
15d ago
PCRX
Pacira to be acquired by Viatris in cash deal
PremiumCompany Announcements
Pacira to be acquired by Viatris in cash deal
15d ago
8K
PCRX
Viatris: Pacira deal expected to be immediately accretive to financial guidance
PremiumThe Fly
Viatris: Pacira deal expected to be immediately accretive to financial guidance
15d ago
PCRX
VTRS
Viatris to acquire Pacira for $36.50 per share in cash, or $1.65B
PremiumThe Fly
Viatris to acquire Pacira for $36.50 per share in cash, or $1.65B
15d ago
PCRX
VTRS
Viatris to acquire Pacira for $36.50 per share in cash, or $1.65B
PremiumThe Fly
Viatris to acquire Pacira for $36.50 per share in cash, or $1.65B
15d ago
PCRX
VTRS
Pacira price target raised to $31 from $30 at Truist
PremiumThe FlyPacira price target raised to $31 from $30 at Truist
16d ago
PCRX
Pacira, Molteni Farmaceutici to expand postsurgical pain management access
Premium
The Fly
Pacira, Molteni Farmaceutici to expand postsurgical pain management access
18d ago
PCRX
Pacira initiated with an Outperform at Oppenheimer
Premium
The Fly
Pacira initiated with an Outperform at Oppenheimer
30d ago
PCRX
Pacira initiated with a Market Perform at Leerink amid ‘formulary inertia’
PremiumThe Fly
Pacira initiated with a Market Perform at Leerink amid ‘formulary inertia’
1M ago
PCRX
Pacira initiated with a Market Perform at Leerink
PremiumThe Fly
Pacira initiated with a Market Perform at Leerink
1M ago
PCRX
Analyst Initiates Buy on Pacira, Citing Durable Exparel Growth and Pipeline Upside with $30 Price Target
PremiumRatings
Analyst Initiates Buy on Pacira, Citing Durable Exparel Growth and Pipeline Upside with $30 Price Target
2M ago
PCRX
Pacira reinstated with a Buy at Truist
PremiumThe Fly
Pacira reinstated with a Buy at Truist
2M ago
PCRX
Pacira Earnings Call: Growth, Margins and Pipeline
PremiumCompany AnnouncementsPacira Earnings Call: Growth, Margins and Pipeline
3M ago
PCRX
Pacira price target raised to $25 from $24 at RBC Capital
Premium
The Fly
Pacira price target raised to $25 from $24 at RBC Capital
3M ago
PCRX
Pacira cuts FY26 revenue view to $735M-$760M from $745M-$770M,
Premium
The Fly
Pacira cuts FY26 revenue view to $735M-$760M from $745M-$770M,
3M ago
PCRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >